We appreciate Li and Liu1 for their interests in and comments on our article.2 Although most patients with severe coronavirus disease 2019 (COVID-19) have a self-limited disease course, about 10% to 15% subsequently developed critical illness and experienced a high mortality.3,4 In our randomized controlled trial, we evaluated whether the use of ruxolitinib was safe and superior in shortening the time to recovery and in preventing severe COVID-19 from progression. Given below are our point-to-point responses to each of the comments.
We read with great interest the article titled ‘‘Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial’’ by Cao et al.1 The study, which finally included 41 patients, evaluated the efficacy and safety of ruxolitinib for severe COVID-19 cases. They finally found that ruxolitinib recipients had a significant chest computed tomography (CT) improvement, a faster recovery from lymphopenia, and favorable side-effect profile. However, we think it is appropriate to comment on the methods used in this study.
This is the largest interventional clinical study performed in patients with HES to date and demonstrates for the first time that mepolizumab is associated with a reduction in disease flares without significant adverse events.
Capsule Summary: We show that severe type 2 CRSwNP patients display a profound neutrophilic inflammation, with increased activation status and proteolytic activity, co-existing with severe eosinophilia (EETosis and CLC-deposition), and independent of IL-17.
Capsule SummaryWe identify an NLRP3 gain-of-function variant that is activated in the colon via post-translational mechanism. It will facilitate diagnosis and precision treatment for patients with NLRP3-associated VEOIBD.